Gritstone Bio (NASDAQ:GRTS Investor Three-year Losses Grow to 85% as the Stock Sheds US$57m This Past Week
Gritstone Bio (NASDAQ:GRTS Investor Three-year Losses Grow to 85% as the Stock Sheds US$57m This Past Week
Gritstone bio, Inc. (NASDAQ:GRTS) shareholders should be happy to see the share price up 27% in the last quarter. But that doesn't change the fact that the returns over the last three years have been stomach churning. The share price has sunk like a leaky ship, down 85% in that time. So it's about time shareholders saw some gains. Only time will tell if the company can sustain the turnaround. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.
Gritstone bio, Inc.(纳斯达克股票代码:GRTS)的股东应该很高兴看到上个季度股价上涨27%。但这并不能改变过去三年的回报令人大跌眼镜的事实。股价像一艘漏水的船一样下跌,在那段时间内下跌了85%。因此,现在是股东看到一些收益的时候了。只有时间才能证明公司能否维持这种转变。我们真的希望任何在价格暴跌中保持不变的人都能拥有多元化的投资组合。即使你赔了钱,你也不必输掉这堂课。
If the past week is anything to go by, investor sentiment for Gritstone bio isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
如果说过去一周有意义的话,投资者对Gritstone bio的情绪并不乐观,所以让我们看看基本面与股价之间是否存在不匹配的情况。
Given that Gritstone bio didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
鉴于Gritstone bio在过去十二个月中没有盈利,我们将专注于收入增长,以快速了解其业务发展。当一家公司没有盈利时,我们通常预计收入会有良好的增长。可以想象,收入的快速增长如果持续下去,通常会带来利润的快速增长。
In the last three years Gritstone bio saw its revenue shrink by 18% per year. That means its revenue trend is very weak compared to other loss making companies. The swift share price decline at an annual compound rate of 23%, reflects this weak fundamental performance. We prefer leave it to clowns to try to catch falling knives, like this stock. There is a good reason that investors often describe buying a sharply falling stock price as 'trying to catch a falling knife'. Think about it.
在过去的三年中,Gritstone bio的收入每年减少18%。这意味着与其他亏损公司相比,其收入趋势非常疲软。股价以23%的年复合率迅速下跌,反映了这种疲软的基本面表现。我们更愿意让小丑去抓掉落的刀具,比如这只股票。投资者经常将买入大幅下跌的股价描述为 “试图抓住一把下跌的刀”,这是有充分理由的。想一想。
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
下图显示了收入和收入随时间推移的跟踪情况(如果您点击图片,可以看到更多细节)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240305/0-ea843306253a0f3b09a1223045abeec6-0-59f8ba50a2ec41a0ab69fe5524ff5fc2.png/big)
Take a more thorough look at Gritstone bio's financial health with this free report on its balance sheet.
通过这份免费的资产负债表报告,更全面地了解Gritstone bio的财务状况。
A Different Perspective
不同的视角
While the broader market gained around 29% in the last year, Gritstone bio shareholders lost 9.0%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, longer term shareholders are suffering worse, given the loss of 12% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 4 warning signs for Gritstone bio (of which 2 are concerning!) you should know about.
去年整体市场上涨了约29%,而Gritstone生物股东却下跌了9.0%。但是,请记住,即使是最好的股票有时也会在十二个月内表现不如市场。不幸的是,鉴于过去五年中损失了12%,长期股东遭受的损失更加严重。在认为股价将稳定之前,我们希望获得明确的信息,表明该公司将增长。尽管市场状况可能对股价产生的不同影响值得考虑,但还有其他因素更为重要。比如风险。每家公司都有它们,我们已经发现了Gritstone bio的4个警告信号(其中2个令人担忧!)你应该知道。
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。